Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; hyprolose; purified talc; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400; indigo carmine aluminium lake - prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. prophylaxis of organ rejection in paediatric patients (with a body surface area > 1.5 m2) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; hyprolose; povidone; purified talc; magnesium stearate; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400; indigo carmine aluminium lake - prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. prophylaxis of organ rejection in paediatric patients (with a body surface area > 1.5 m2) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 1 g - tablet, modified release - excipient ingredients: magnesium stearate; purified talc; ethylcellulose; povidone; microcrystalline cellulose - treatment of mild to moderate ulcerative colitis and crohn's disease and maintenance of remission.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: sodium carbonate; glycine; povidone; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; calcium stearate; hypromellose; methacrylic acid copolymer; purified talc; titanium dioxide; iron oxide yellow; macrogol 6000; basic butylated methacrylate copolymer - salofalk granules and tablets are indicated in the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis. treatment of acute episodes and maintenance of remission of crohn's ileitis and colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sirolimus, quantity: 1 mg - tablet, sugar coated - excipient ingredients: titanium dioxide; magnesium stearate; purified talc; lactose monohydrate; carnauba wax; poloxamer; povidone; microcrystalline cellulose; dl-alpha-tocopherol; macrogol 20000; glyceryl monooleate; shellac; calcium sulfate; sucrose; macrogol 8000; propylene glycol; butan-1-ol; isopropyl alcohol; iron oxide red; strong ammonia solution; simethicone; ethanol; sulfuric acid - indications as at 9 february 2004: rapamune is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants. therapeutic drug monitoring of sirolimus is required.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tofacitinib citrate, quantity: 8.078 mg (equivalent: tofacitinib, qty 5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; triacetin; macrogol 3350 - rheumatoid arthritis (ra),xeljanz is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults who have had an inadequate response or are intolerant to methotrexate. xeljanz can be used alone or in combination with conventional synthetic disease-modifying antirheumatic drugs (dmards), including methotrexate. psoriatic arthritis (psa),xeljanz in combination with conventional synthetic dmards is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response to a prior dmard therapy. ulcerative colitis (uc),xeljanz is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biological therapy.,ankylosing spondylitis (as),xeljanz is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.,juvenile idiopathic arthritis (jia),xeljanz is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis, extended oligoarthritis and systemic juvenile arthritis without systemic features for six months) and juvenile psoriatic arthritis in patients 2 years of age and older, who have responded inadequately to previous therapy with dmards.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 500 mg - tablet, modified release - excipient ingredients: purified talc; ethylcellulose; povidone; microcrystalline cellulose; magnesium stearate - treatment of mild to moderate ulcerative colitis and crohn's disease and maintenance of remission.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - mycophenolate sodium, quantity: 384.8 mg - tablet, enteric coated - excipient ingredients: crospovidone; maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; iron oxide red; hypromellose phthalate; iron oxide yellow; povidone; lactose - myfortic is indicated for the prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplants. myfortic is indicated for induction and maintenance treatment of adult patients with who class iii, iv or v lupus nephritis. this indication is based on the evidence in literature reports of studies of treatment in patients with lupus nephritis, the majority of whom were isn/rps (2003) class iv. the evidence for efficacy was based on surrogate endpoints.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - mycophenolate sodium, quantity: 192.4 mg - tablet, enteric coated - excipient ingredients: colloidal anhydrous silica; hypromellose phthalate; maize starch; indigo carmine; povidone; titanium dioxide; magnesium stearate; crospovidone; iron oxide yellow; lactose - myfortic is indicated for the prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplants. myfortic is indicated for induction and maintenance treatment of adult patients with who class iii, iv or v lupus nephritis. this indication is based on the evidence in literature reports of studies of treatment in patients with lupus nephritis, the majority of whom were isn/rps (2003) class iv. the evidence for efficacy was based on surrogate endpoints.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; purified talc; povidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; hyprolose; iron oxide red; macrogol 400 - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.